Transcode Therapeutics Files 2024 Annual Report Amendment
Ticker: RNAZ · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1829635
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
TL;DR
Transcode Therapeutics filed its 2024 10-K amendment on 4/30/25. Check for updates.
AI Summary
Transcode Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Delaware and headquartered in Boston, MA, operates in the pharmaceutical preparations sector. This filing provides updated information for the period ending December 31, 2024, with the amendment filed on April 30, 2025.
Why It Matters
This amendment to the annual report provides updated financial and operational information for Transcode Therapeutics, Inc., crucial for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This filing is an amendment to an annual report, primarily providing updated information rather than announcing new material events.
Key Numbers
- 2024 — Fiscal Year End (The annual report covers the period ending December 31, 2024.)
- 20250430 — Filing Date (The amendment to the 10-K was filed on this date.)
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Registrant
- December 31, 2024 (date) — Fiscal year end
- April 30, 2025 (date) — Filing date of amendment
- Boston, MA (location) — Company headquarters
- 001-40363 (company_id) — Commission File Number
FAQ
What is the primary purpose of this 10-K/A filing?
This 10-K/A filing is an amendment to the annual report for the fiscal year ended December 31, 2024, providing updated information.
When was the original 10-K filed or when is the fiscal year end being reported?
The fiscal year end being reported is December 31, 2024, and the amendment was filed on April 30, 2025.
What is the company's full legal name and state of incorporation?
The company's full legal name is Transcode Therapeutics, Inc., and it is incorporated in Delaware.
Where is Transcode Therapeutics, Inc. located?
The company's business and mailing address is 6 Liberty Square, #2382, Boston, MA 02109.
What is the Commission File Number for Transcode Therapeutics, Inc.?
The Commission File Number is 001-40363.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding Transcode Therapeutics, Inc. (RNAZ).